Lysine 117 on ataxin-3 modulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3
Jessica R. Blount, Nikhil C. PateliD, Kozeta Libohova, Autumn L. Harris, Wei‐Ling TsouiD, Alyson L. SujkowskiiD, Sokol V. TodiiD
Abstract
Ataxin-3 (Atxn3) is a deubiquitinase with a polyglutamine (polyQ) repeat tract whose abnormal expansion causes the neurodegenerative disease, Spinocerebellar Ataxia Type 3 (SCA3; also known as Machado-Joseph Disease). The ubiquitin chain cleavage properties of Atxn3 are enhanced when it is ubiquitinated at lysine (K) at position 117. K117-ubiqutinated Atxn3 cleaves poly-ubiquitin more rapidly in vitro compared to its unmodified counterpart and this residue is also important for Atxn3 roles in cell culture and in Drosophila melanogaster. How polyQ expansion causes SCA3 remains unclear. To gather insight into the biology of disease of SCA3, here we posited the question: is K117 important for toxicity caused by Atxn3? We generated transgenic Drosophila lines that express full-length, human, pathogenic Atxn3 with 80 polyQ with an intact or mutated K117. We found that K117 mutation mildly enhances the toxicity and aggregation of pathogenic Atxn3 in Drosophila. An additional transgenic line that expresses Atxn3 without any K residues confirms increased aggregation of pathogenic Atxn3 whose ubiquitination is perturbed. These findings suggest Atxn3 ubiquitination as a regulatory step of SCA3, in part by modulating its aggregation.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 6
- FWCI
- 0.73
- Field percentile
- top 35%
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Regional and age-dependent changes in ubiquitination in cellular and mouse models of Spinocerebellar ataxia type 3
Haiyang Luo, Sokol V. Todi, … Maria do Carmo Costa·Frontiers in Molecular NeurosciencePeer-reviewed·Apr 14, 2023
- Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia Type 3 disease protein
Naila S. Ashraf, Joanna R. Sutton, … Maria do Carmo Costa·Neurobiology of DiseasePeer-reviewed·Nov 26, 2019
- A novel Ataxin-3 knock-in mouse model mimics the human SCA3 disease phenotype including neuropathological, behavioral, and transcriptional abnormalities
Eva Haas, Rana Dilara Incebacak Eltemur, … Jeannette Hübener‐Schmid·bioRxiv·Feb 28, 2020
- Autophagosome-tethering compounds selectively lower mutant ataxin-3 in preclinical models of spinocerebellar ataxia type 3
Hongyu Yuan, Zhao Chen, … Hong Jiang·bioRxiv·Oct 8, 2026
- Treatment with sodium butyrate induces autophagy resulting in therapeutic benefits for spinocerebellar ataxia type 3
Maxinne Watchon, Katherine J. Robinson, … Angela S. Laird·The FASEB JournalPeer-reviewed·Jan 23, 2024
- Flow cytometry allows rapid detection of protein aggregates in cell culture and zebrafish models of spinocerebellar ataxia-3
Katherine J. Robinson, Madelaine C. Tym, … Angela S. Laird·Disease Models & MechanismsPeer-reviewed·Sep 2, 2021